Erythromycin

證據等級: L5

預測適應症: 10 個

Erythromycin: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Erythromycin is a macrolide antibiotic with broad-spectrum activity, historically used to treat bacterial infections of the respiratory tract, skin, and sexually transmitted infections including chlamydial disease. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, with 0 clinical trials and 2 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	No Singapore (HSA) registration — known use: broad-spectrum bacterial infections
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.89%
Evidence Level	L4
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding reversibly to the 50S ribosomal subunit, blocking translocation of aminoacyl-tRNA and halting polypeptide chain elongation. This mechanism confers activity against gram-positive organisms (notably Staphylococcus aureus, Streptococcus spp.) and atypical intracellular pathogens including Chlamydia trachomatis — organisms frequently implicated in lid margin disease.

Punctate epithelial keratoconjunctivitis (PEK) is a non-specific corneal condition characterised by fine epithelial erosions and is often secondary to chronic blepharitis, meibomian gland dysfunction, or infectious conjunctivitis. Erythromycin ophthalmic ointment is an established standard-of-care agent for bacterial blepharitis and blepharokeratoconjunctivitis — conditions that share direct pathophysiological overlap with PEK. When lid margin staphylococcal colonisation or chlamydial infection is the root trigger, erythromycin's anti-staphylococcal and anti-chlamydial coverage provides a mechanistically plausible pathway to corneal epithelial improvement.

However, this remains a mechanism-based hypothesis. No study directly evaluates erythromycin as a therapy for PEK as a primary endpoint, and the TxGNN prediction likely reflects the drug–disease network proximity via the blepharitis–PEK pathophysiological bridge rather than direct clinical evidence. L4 evidence tier: the prediction is biologically rational but unverified in controlled trials.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11495307	2001	Review / Management Guideline	Journal of Pediatric Ophthalmology and Strabismus	Reviews history, symptoms, clinical signs, and treatment strategies for chronic blepharokeratoconjunctivitis in children — a condition mechanistically linked to punctate epithelial changes; erythromycin is among discussed antimicrobial options
32826651	2021	Case Report	Cornea	Dual molecular diagnosis of microsporidia (Encephalitozoon hellem) keratoconjunctivitis in an immunocompetent adult via metagenomic sequencing — illustrates the breadth of infectious etiologies requiring targeted antimicrobial therapy in keratoconjunctivitis

Singapore Market Information

Erythromycin is not registered with the Health Sciences Authority (HSA) of Singapore. No product licences are on record in the HSA database.

Safety Considerations

Please refer to the package insert for safety information.

Note: Formal safety data (key warnings, contraindications, drug–drug interactions) were not available in this evidence pack. TFDA package insert review is identified as a blocking data gap (DG001) and must be completed before any clinical evaluation proceeds.

Additional Noteworthy Predictions

While this report focuses on the top-ranked TxGNN prediction, two lower-ranked indications carry substantively stronger clinical evidence and may warrant prioritised investigation over Punctate Epithelial Keratoconjunctivitis:

Lymphogranuloma Venereum (Rank 4 | L3 | "Proceed with Guardrails") LGV is caused by Chlamydia trachomatis serovars L1–L3. Erythromycin has a documented historical role as an alternative treatment (particularly in pregnancy, 21-day course) in WHO/CDC guidelines. One completed Phase 4 RCT (NCT03608774, n=177) confirms macrolide class efficacy; a 1955 clinical publication (PMID 13239093) directly records erythromycin use in early LGV. Evidence level L3 supports further evaluation pending local STI guideline alignment.

Necrotising Ulcerative Gingivitis (Rank 5 | L3 | "Proceed with Guardrails") Vincent's angina is a mixed anaerobic infection (Fusobacterium nucleatum / Treponema vincentii). PMID 13221896 (1953) provides direct historical clinical evidence of erythromycin ("Ilotycin") for fusospirochetal oropharyngeal infection; PMID 6589179 (1984) identifies erythromycin as a second-line antibiotic of choice in dental infections for penicillin-allergic patients. Evidence is pre-RCT era but has direct drug–disease correspondence.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a very high prediction score (99.89%) reflecting strong network proximity, but the mechanistic link to Punctate Epithelial Keratoconjunctivitis is indirect — bridged via established blepharitis use rather than direct evidence. With zero registered clinical trials and only two tangentially related publications, the evidence does not meet the threshold for clinical deployment.

To proceed, the following is needed:

Retrieve official MOA data from DrugBank (DG002) to formalise the mechanistic rationale
Obtain TFDA package insert (DG001) for key warnings, contraindications, and drug interactions — this is a blocking prerequisite for any safety evaluation
Commission a systematic literature search specifically combining erythromycin + PEK or erythromycin ophthalmic ointment + corneal epithelial disease
Determine causative aetiology in target PEK patients (bacterial vs. viral vs. toxic/allergic) — antibiotic therapy is only appropriate for the bacterial subset
Consider redirecting near-term clinical evaluation to Lymphogranuloma Venereum (Rank 4, L3) or Necrotising Ulcerative Gingivitis (Rank 5, L3), where evidence maturity is substantively higher
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.